Dec 20, 2013

AbbVie to Present at 32nd Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Dec. 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 11 a.m. Central time.

Dec 10, 2013

AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C

NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with chronic, genotype 1 (GT1) hepatitis C virus (HCV) infection. In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR12) with the regimen. The majority of patients were GT1a, considered a difficult-to-treat subtype, and the SVR12 rates of GT1a and GT1b were 96 percent and 97 percent, respectively. Virologic relapse or breakthrough was noted in 2 percent of patients receiving the 3D regimen plus ribavirin. In addition, the discontinuation rate due to adverse events was 1 percent.

Nov 26, 2013

AbbVie Partners with HIV Community to Launch International Awareness Campaign Focused on Women Living with HIV

NORTH CHICAGO, Ill., Nov. 26, 2013 /PRNewswire/ -- In advance of World AIDS Day on December 1, 2013, AbbVie (NYSE: ABBV) today announced the launch of See Us: Women Take a Stand on HIV, an international awareness campaign focused on helping to address the unique challenges faced by women living with HIV. The campaign is being launched in collaboration with an expert steering committee, which includes representation from women living with and affected by HIV, the medical community, the International Association of Providers in AIDS Care (IAPAC), and NAM/aidsmap, the HIV information charity.

Nov 18, 2013

AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR12) of 96 percent. The majority of patients were GT1a, considered the more difficult-to-treat subtype, and the SVR12 rates of GT1a and GT1b were 95 percent and 98 percent, respectively. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen. In addition, discontinuation rates due to adverse events were low, and of an equal percentage (0.6 percent) in both active and placebo groups.

Nov 18, 2013

AbbVie and North Chicago Public Schools Announce $350,000 Grant to Advance Math Education

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie, one of the nation's largest biopharmaceutical companies, and the North Chicago public schools announce a $350,000 grant for math education.  The grant will enable educators to strengthen and reinforce the math curriculum for students (K-8) in the district and assist in the implementation of an engaging, common core aligned curriculum designed to increase both the educator and student understanding of and proficiency in mathematics.

Nov 14, 2013

AbbVie to Present at Jefferies 2013 Healthcare Conference

NORTH CHICAGO, Ill., Nov. 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2013 Healthcare Conference on Thursday, Nov. 21, 2013. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 10:40 a.m. Greenwich Meantime (4:40 a.m. Central time).

Nov 07, 2013

AbbVie to Present at Credit Suisse 2013 Healthcare Conference

NORTH CHICAGO, Ill, Nov. 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2013 Healthcare Conference on Thursday, Nov. 14, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 9:30 a.m. Central time.

Nov 06, 2013

New Survey Reveals More than Half of Americans are Living with Gastrointestinal Symptoms and Not Seeking Care from a Doctor

NORTH CHICAGO, Ill., Nov. 6, 2013 /PRNewswire/ -- According to a new, national survey of more than 2,000 U.S. adults, 72 percent said they have experienced at least one of the following gastrointestinal (GI) symptoms a few times a month or more: diarrhea, gas, bloating, stomach pain, frequent bowel movements, unexplained weight-loss and non-specific GI discomfort. Surprisingly, a majority of surveyed participants (74 percent) have lived with their GI symptoms for more than six months. Despite this, more than half (56 percent) of those who have experienced GI discomfort have not spoken with their primary care doctor because they do not believe their symptoms require physician attention.

Oct 25, 2013

AbbVie Reports Third-Quarter 2013 Financial Results

NORTH CHICAGO, Ill., Oct. 25, 2013 /PRNewswire/ --

Oct 24, 2013

AbbVie Named a Science Top Employer

NORTH CHICAGO, Ill., Oct. 24, 2013 /PRNewswire/ -- The journal Science named AbbVie as one of its 2013 Top Employers.  AbbVie ranked fourth in its first year on the annual list, as surveyed by more than 3,000 respondents.